

## MedVital raises Rs 8.4 Cr pre-seed funding to accelerate transformation in skin repair, restoration and regeneration

15 May 2025 | News

**Fresh capital injection will be directed towards expanding MedVital's product portfolio**



Mumbai-based startup MedVital, a new-age medtech startup focused on making advanced and innovative technologies for hard-to-heal wounds and minimally invasive aesthetics more smart and accessible, has raised Rs 8.4 crore in pre-seed funding.

The round was led by Nihar Parikh's 4point0 Health Ventures, with participation from a marquee group of operator-investors, including founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk.

India's healthcare system is undergoing a pivotal shift. A growing burden of hard-to-heal wounds driven by ageing, diabetes, obesity, and trauma is intersecting with the rising demand for minimally invasive aesthetic solutions. At the heart of both lies a shared need for advanced, outcome-oriented, evidence-led technologies that can repair, restore, and regenerate skin. Yet access to such solutions remains limited, held back by systemic gaps in reach and scale.

MedVital is addressing this gap by building India's first integrated platform for complex wound care and minimally invasive aesthetics, two underserved domains despite their clinical urgency. Its flagship brand, NoWound, is a state-of-the-art Negative Pressure Wound Therapy (NPWT) device designed to offer precision-controlled healing across hospital, clinic, and home-care settings. Unlike traditional NPWT systems, NoWound is compact, digitally enabled, and made in India, allowing

seamless deployment even in resource-constrained environments.

This fresh capital injection will be directed towards expanding MedVital's product portfolio, strengthening its supply chain, and broadening its distribution network to cover tertiary care hospitals, rural clinics, and home-care settings.

MedVital will soon launch liquid chitosan-based dressings for hard-to-heal wounds, and expand into dermal and hair regeneration solutions—unlocking new clinical pathways in both therapeutic and aesthetic care.